65.36
price up icon0.63%   +0.41
after-market  After Hours:  62.35  -3.01   -4.61%
loading
ANI Pharmaceuticals Inc stock is currently priced at $65.36, with a 24-hour trading volume of 66,012. It has seen a +0.63% increased in the last 24 hours and a -6.02% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $64.84 pivot point. If it approaches the $65.39 resistance level, significant changes may occur.
Previous Close:
$64.95
Open:
$64.83
24h Volume:
66,012
Market Cap:
$1.37B
Revenue:
$486.82M
Net Income/Loss:
$18.78M
P/E Ratio:
-136.17
EPS:
-0.48
Net Cash Flow:
$100.45M
1W Performance:
-0.18%
1M Performance:
-6.02%
6M Performance:
+8.07%
1Y Performance:
+73.78%
1D Range:
Value
$64.68
$65.60
52W Range:
Value
$37.06
$70.81

ANI Pharmaceuticals Inc Stock (ANIP) Company Profile

Name
Name
ANI Pharmaceuticals Inc
Name
Phone
218-634-3500
Name
Address
210 Main Street West, Baudette, MN
Name
Employee
173
Name
Twitter
Name
Next Earnings Date
2024-05-21
Name
Latest SEC Filings
Name
ANIP's Discussions on Twitter

ANI Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-22-23 Reiterated H.C. Wainwright Buy
Mar-01-23 Initiated Guggenheim Buy
Sep-07-22 Initiated H.C. Wainwright Buy
Nov-02-21 Initiated Truist Buy
May-07-20 Downgrade Cantor Fitzgerald Overweight → Neutral
Sep-12-19 Initiated Guggenheim Buy
May-10-19 Downgrade Raymond James Strong Buy → Outperform
Oct-16-17 Reiterated Canaccord Genuity Buy
Jul-31-17 Initiated Canaccord Genuity Buy
Feb-22-17 Downgrade ROTH Capital Buy → Neutral
Jun-23-16 Initiated Raymond James Strong Buy
May-24-16 Downgrade Standpoint Research Buy → Hold
Nov-13-15 Initiated Standpoint Research Buy
Sep-28-15 Upgrade ROTH Capital Neutral → Buy
Aug-05-15 Reiterated Oppenheimer Outperform
Aug-04-15 Reiterated ROTH Capital Neutral
Jul-31-15 Reiterated Oppenheimer Outperform
Jul-15-15 Reiterated ROTH Capital Neutral
Jun-23-15 Reiterated Oppenheimer Outperform
May-18-15 Reiterated ROTH Capital Neutral
May-06-15 Reiterated Oppenheimer Outperform
Apr-10-15 Downgrade ROTH Capital Buy → Neutral
Feb-26-15 Reiterated ROTH Capital Buy
Feb-18-15 Reiterated Oppenheimer Outperform
View All

ANI Pharmaceuticals Inc Stock (ANIP) Financials Data

ANI Pharmaceuticals Inc (ANIP) Revenue 2024

ANIP reported a revenue (TTM) of $486.82 million for the quarter ending December 31, 2023, a +53.87% rise year-over-year.
loading

ANI Pharmaceuticals Inc (ANIP) Net Income 2024

ANIP net income (TTM) was $18.78 million for the quarter ending December 31, 2023, a +139.21% increase year-over-year.
loading

ANI Pharmaceuticals Inc (ANIP) Cash Flow 2024

ANIP recorded a free cash flow (TTM) of $100.45 million for the quarter ending December 31, 2023, a +310.77% increase year-over-year.
loading

ANI Pharmaceuticals Inc (ANIP) Earnings per Share 2024

ANIP earnings per share (TTM) was $0.82 for the quarter ending December 31, 2023, a +126.97% growth year-over-year.
loading

ANI Pharmaceuticals Inc Stock (ANIP) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
Apr 18 '24
Sale
64.98
10,423
677,287
799,429
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
Apr 17 '24
Sale
65.40
9,520
622,608
809,852
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
Apr 16 '24
Sale
66.20
5,834
386,211
819,372
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
Apr 15 '24
Sale
66.33
7,414
491,771
825,206
Cook Meredith
SR. VP, GENERAL COUNSEL & SEC.
Apr 12 '24
Sale
67.79
250
16,948
59,731
Gassert Chad
SVP - CORP. DEV. & STRATEGY
Apr 01 '24
Sale
67.25
20,000
1,345,000
253,226
Cook Meredith
SR. VP, GENERAL COUNSEL & SEC.
Mar 13 '24
Sale
66.54
250
16,635
59,981
Gassert Chad
SVP - CORP. DEV. & STRATEGY
Mar 11 '24
Sale
65.81
20,000
1,316,200
273,226
CAREY STEPHEN P.
SVP & CFO
Mar 11 '24
Sale
65.55
7,787
510,438
177,712
Lalwani Nikhil
PRESIDENT & CEO
Mar 08 '24
Sale
67.13
16,292
1,093,682
411,629
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis. It also provides Hydrocortisone Rectal Cream to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Lithium Carbonate ER and Lithobid for bipolar disorder; Mesalamine Enema to treat distal ulcerative colitis, proctosigmoiditis, or proctitis; Methazolamide to treat ocular conditions; and Metoclopramide and Reglan to treat gastroesophageal reflux. In addition, the company offers Nilutamide to treat metastatic prostate cancer; Nimodipine that reduces the ischemic deficits in patients with subarachnoid hemorrhage; Opium Tincture to treat diarrhea; Oxycodone capsules and oral solution for severe and chronic pain; Propafenone to treat arrhythmia; Propranolol ER, Inderal LA, and Pindolol for managing hypertension in patients with angina pectoris; and Vancomycin and Vancocin for use in treating C. difficile-associated diarrhea and enterocolitis. Further, it provides contract manufacturing services for other pharmaceutical companies. The company markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota.
$13.26
price up icon 1.69%
$73.26
price up icon 1.57%
$55.92
price up icon 0.22%
drug_manufacturers_specialty_generic RDY
$74.55
price up icon 0.72%
$135.99
price down icon 1.28%
$11.57
price up icon 0.87%
Cap:     |  Volume (24h):